NetworkNewsBreaks – India Globalization Capital
Post# of 436
(Total Views: 1210)
Posted On: 11/06/2017 6:19:48 PM
NetworkNewsBreaks – India Globalization Capital (NYSE: IGC) Avoids Regulatory Costs through Cannabis-based Drug Candidates
India Globalization Capital (NYSE AMERICAN: IGC) is developing a portfolio of products using cannabis-based “combination therapies” for the treatment of various life-altering conditions. The company is employing a distinctive strategy to bring these drug candidates to market. An article discussing this reads: “IGC’s unique strategy reduces regulatory approval time and development costs because its chosen categories face lower regulatory burdens. Instead of pursuing full novel drug applications, which take anywhere from 7-9 years in clinical trials and cost hundreds of millions before securing FDA approval, IGC is developing cannabis-based drugs that could be commercialized in less than two years and at a cost of between $2 million and $3 million per product. These products will then be made available through medical cannabis dispensaries, which means a faster development timeline with a much lower end cost than through the traditional pharmaceutical pipeline.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
India Globalization Capital (NYSE AMERICAN: IGC) is developing a portfolio of products using cannabis-based “combination therapies” for the treatment of various life-altering conditions. The company is employing a distinctive strategy to bring these drug candidates to market. An article discussing this reads: “IGC’s unique strategy reduces regulatory approval time and development costs because its chosen categories face lower regulatory burdens. Instead of pursuing full novel drug applications, which take anywhere from 7-9 years in clinical trials and cost hundreds of millions before securing FDA approval, IGC is developing cannabis-based drugs that could be commercialized in less than two years and at a cost of between $2 million and $3 million per product. These products will then be made available through medical cannabis dispensaries, which means a faster development timeline with a much lower end cost than through the traditional pharmaceutical pipeline.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)